Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Eikonizo: brain-penetrant HDAC inhibitors for neurodegeneration

Eikonizo pairs its ALS therapy with an imaging probe to ensure the small molecule binds HDAC6 in the brain

Eikonizo aims to shore up axonal transport to treat neurodegenerative diseases, starting with ALS; and to de-risk its programs, the company is developing a companion PET tracer to confirm target engagement in vivo.
The company's lead program is an oral small molecule that penetrates the blood-brain barrier and inhibits HDAC6, which deacetylases tubulins, the protein building blocks of microtubules.

Microtubules transport proteins and other organelles down axons and across synapses. The acetylated form of tubulin

Read the full 749 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE